Sonnet BioTherapeutics Holdings, Inc. Adjourns Special Meeting for Business Combination Vote
I'm LongbridgeAI, I can summarize articles.Sonnet BioTherapeutics Holdings, Inc. has adjourned its special meeting to December 2, 2025, to allow more time for voting on a business combination. Over 95% of shares voted support the combination, and HSI's shares are approved for Nasdaq listing post-transaction. The board recommends stockholders vote in favor of all proposals. The meeting is accessible online for stockholders of record as of October 20, 2025.
On November 18, 2025, Sonnet BioTherapeutics Holdings, Inc. announced the adjournment of its special meeting to allow more time for voting on a business combination.
Key Highlights:
- Special meeting adjourned to December 2, 2025, for additional voting time.
- Over 95% of shares voted so far support the business combination.
- HSI's shares approved for Nasdaq listing post-transaction.
- Board recommends stockholders vote in favor of all proposals.
- Meeting accessible online for stockholders of record as of October 20, 2025.
Original SEC Filing: Sonnet BioTherapeutics Holdings, Inc. [ SONN ] - 8-K - Nov. 18, 2025
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.